Schrodinger
Computational drug designing for pharmaceutical and biotechnology research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $10.0m | Grant | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 28 % | 31 % | 20 % | (4 %) | 22 % | 22 % | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (87 %) | (69 %) | (104 %) | (101 %) | (73 %) | (53 %) | (23 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (73 %) | (82 %) | 19 % | (90 %) | (77 %) | (55 %) | (28 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 66 % | 70 % | 84 % | 97 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Schrödinger operates a cutting-edge computational platform that supports the research initiatives of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Founded in 1990, the company is dedicated to advancing science and talent to enhance its platform. Schrödinger also engages in both wholly-owned and collaborative drug discovery programs across various therapeutic areas. The business model revolves around providing advanced computational tools and services to its clients, which include a diverse range of organizations in over 70 countries. Revenue is generated through software licensing, collaborative research agreements, and drug discovery partnerships.
Keywords: computational platform, biopharmaceutical research, drug discovery, academic institutions, government laboratories, therapeutic areas, software licensing, collaborative research, global reach, science investment.
Tech stack
Investments by Schrodinger
Edit
